Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 901 to 915 of 1340 results for 0

  1. Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)

    Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma in adults.

  2. Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.

  3. Lateral interbody fusion in the lumbar spine for low back pain (IPG574)

    Evidence-based recommendations on lateral interbody fusion in the lumbar spine for low back pain in adults. This involves removing the damaged disc and fixing parts of the spine together, to relieve pain.

  4. Endoscopic thoracic sympathectomy for primary facial blushing (IPG480)

    Evidence-based recommendations on endoscopic thoracic sympathectomy for primary facial blushing. This involves cutting off nerve signals to stop the blushing.

  5. WoundExpress to manage lower leg wounds (MIB261)

    NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .

  6. Esketamine nasal spray for treatment-resistant depression (TA854)

    Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.

  7. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

  8. Shiley Endotracheal Tube with TaperGuard Cuff for intensive care patients at risk of ventilator‑associated pneumonia (MIB22)

    NICE has developed a medtech innovation briefing (MIB) on the Shiley Endotracheal Tube with TaperGuard Cuff .

  9. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254)

    Evidence-based recommendations on fingolimod (Gilenya) for highly active relapsing-remitting multiple sclerosis.

  10. Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

    Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

  11. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)

    Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.

  12. Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

    Discontinued Reference number: GID-TA10585

  13. Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]

    Discontinued Reference number: GID-TA10355

  14. Social and emotional wellbeing: early years (PH40)

    This guideline covers supporting the social and emotional wellbeing of vulnerable children under 5 through home visiting, childcare and early education. It aims to optimise care for young children who need extra support because they have or are at risk of social or emotional problems.

  15. Thermogard XP for therapeutic hypothermia after cardiac arrest (MIB37)

    NICE has developed a medtech innovation briefing (MIB) on Thermogard XP for therapeutic hypothermia after cardiac arrest